



WellSpring Pharmaceutical Facility Accepted by FDA to Manufacture Pharmaceutical Products

Approval Enhances Ability to Provide Contract Pharmaceutical Manufacturing Services to the U.S. Market

OAKVILLE, ONTARIO, September 1, 2003 - WellSpring Pharmaceutical Corporation is pleased to announce its most recent milestone: the U.S. Food and Drug Administration (FDA) has provided a letter of acceptance to WellSpring Pharmaceutical Canada Corp., its contract pharmaceutical manufacturing subsidiary, to manufacture solid and semi-solid dosage form products, such as tablets, capsules, creams, lotions, ointments, gels and non-sterile liquids for the U.S. market. This FDA acceptance enhances WellSpring's ability to expand its customer base for the production of pharmaceutical products in the U.S. and other international markets.

The notice from the FDA follows a recent full quality systems-based cGMP inspection of the Company's pharmaceutical manufacturing facility in Oakville, Ontario. The FDA's resulting Establishment Inspection Report (EIR) incorporated a general cGMP (current Good Manufacturing Practices) review of WellSpring's operations and pharmaceutical systems. WellSpring was found to be operating in a state of control and the facility was classified as acceptable.

"Maintaining the highest standards of cGMP regulatory compliance is central to our long term strategic plan for growing our contract services business in the international marketplace," said Bonnie Feeney, President and COO of WellSpring Pharmaceutical Canada. "This FDA approval of our operation significantly enhances our ability to attract new contract services customers by accelerating FDA's approval of our customers' products at our site and to increase the capacity utilization of our manufacturing facility."

As a result of receiving FDA site approval for its operations, WellSpring now has enhanced capabilities to offer U.S. customers full service, cGMP compliant contract clinical and commercial manufacturing and packaging services for a wide range of pharmaceutical products, including tablets, capsules, creams, lotions, ointments, gels and non-sterile liquids.

About WellSpring Pharmaceutical Canada Corp.:

WellSpring Pharmaceutical Canada Corp. is a contract pharmaceutical manufacturer with capabilities in a broad range of non-sterile dosage forms. Operating out of a cGMP-compliant 101,000 square-foot facility located in Oakville, Ontario, WellSpring manufactures and packages pharmaceutical products for 13 pharmaceutical clients for many international jurisdictions.

About WellSpring Pharmaceutical Corporation:

WellSpring Pharmaceutical Corporation is a specialty pharmaceutical company focused on the development and marketing of niche products that are licensed or purchased from the major pharmaceutical companies and provides contract clinical and commercial pharmaceutical manufacturing services.

For Further Information Please Contact:

Sam Ricchezza
Phone: (905)337-4533
Fax: (905)337-7239
www.wpcoutsourcing.com

